[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Hamada S, Ito K, Kanbara T, Yoshii T, Sato K, Sumitomo M, Kimura F, Asano T: [A case of malignant lymphoma mimicking a seminal vesicle tumor]. Hinyokika Kiyo; 2010 Jul;56(7):393-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant lymphoma mimicking a seminal vesicle tumor].
  • Abdominal computed tomography (CT) showed a mass 7 cm in diameter mimicking a seminal vesicle tumor and magnetic resonance imaging showed a heterogeneously enhanced mass with an unclear borderline to the rectum.
  • The differential diagnosis of the lesion included a tumor arising from a seminal vesicle, a local recurrence of rectal cancer, a rectal GIST, and a mesenchymal tumor.
  • Chest and abdominal CT showed no specific findings except the lesion for the seminal vesicle lesion, but positron emission tomography showed accumulations in the gastrointestinal tract, pleura, and lymph nodes.
  • The patient was thus determined to have stage IV malignant lymphoma and was given two courses of combination chemotherapy including RCHOP.
  • The tumor responded to one course, but the patient died of neutropenic sepsis during the second course.
  • [MeSH-major] Genital Neoplasms, Male / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Seminal Vesicles
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20724815.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Chheda N, Bolegave M, Shet T, Tongaonkar H: Recurrent mullerian adenosarcoma like tumor of seminal vesicle. Indian J Pathol Microbiol; 2010 Apr-Jun;53(2):342-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent mullerian adenosarcoma like tumor of seminal vesicle.
  • Adenosarcoma like tumor of the seminal vesicle is reported herein.
  • A 35-year-old male presented with mass in the pelvis between bladder and rectum, involving the seminal vesicle and prostate.
  • Histologically, the tumor was multicystic with bland ciliated lining epithelium and sarcomatous stroma.
  • A wide excision was performed followed with chemotherapy and radiotherapy.
  • [MeSH-major] Adenosarcoma / diagnosis. Adenosarcoma / pathology. Seminal Vesicles / pathology. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Drug Therapy / methods. Histocytochemistry. Humans. Male. Microscopy. Recurrence. Tomography, X-Ray Computed. Urography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551553.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Haut MJ, Harryhill JF, Rosenstock J, Warhol MJ, Vitti R: Progressing prostate carcinoma. Oncologist; 2001;6(2):183-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the Karnell Cancer Center Grand Rounds, we present a patient who underwent radical prostatectomy with bilateral pelvic lymphadenectomy, but had positive margins and subsequently developed local recurrence and then systemic disease.
  • Therapeutic options at different stages of the disease are examined from the point of view of the urologist, radiation oncologist, and medical oncologist.
  • The surgical portion of the discussion focuses on the selection of initial therapy.
  • Both the selection of surgical candidates and choice of pre- or post-operative therapy in patients can be aided by prognostic tools looking at several variables, including prostate-specific antigen (PSA) level, Gleason score of the tumor, seminal vesicle invasion, extracapsular invasion, and lymph node involvement.
  • Low-risk patients can be treated with monotherapy, such as radical prostatectomy, external beam radiation therapy, prostate brachytherapy, or cryosurgical ablation of the prostate.
  • Higher risk patients may require adjuvant and possibly neoadjuvant therapy in addition.
  • The radiation portion of the discussion focuses on the use of radiation therapy as salvage for relapsing disease.
  • Of particular importance is the point that treating high-risk patients whose PSA levels have started to rise but are less than 1 ng/ml results in a long-term PSA control rate as high as 75%, but that limiting the use of salvage radiation therapy to patients with high PSA levels or biopsy confirmation of local recurrence in the face of a negative bone scan results in biochemical long-term control of less than 40%.
  • In the medical oncology part of the discussion, the major focus is on the use of chemotherapy to treat patients whose disease has become resistant to hormonal therapy.
  • Combination therapy with estramustine plus taxanes, other microtubule inhibitors, or other agents such as topoisomerase II inhibitors, has been found to cause shrinkage of measurable soft tissue disease and diminution of serum PSA levels.
  • The development of effective hormonal and chemotherapeutic drugs for treatment of metastatic disease has led to new interest in adjuvant and neoadjuvant therapy of high-risk patients.
  • [MeSH-minor] Aged. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Prognosis. Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Hyperplasia / pathology. Radiotherapy, Conformal. Survival Rate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11306730.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


Advertisement
4. Losa CA, Fernando AB, Lázaro VA, Berlanga FF, Frago PS, López MA, Sanz MJ, Martínez PG, Sanz LA: [Current value of seminal vesicle biopsy in patients with prostate cancer and influence of radical prostatectomy in patients with seminal vesicle invasion]. Arch Esp Urol; 2006 Dec;59(10):977-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current value of seminal vesicle biopsy in patients with prostate cancer and influence of radical prostatectomy in patients with seminal vesicle invasion].
  • [Transliterated title] Valor actual de la biopsia de vesículas seminales en pacientes con cancer de próstata e influencia de la prostatectomía radical en pacientes con infiltarción seminal.
  • OBJECTIVES: To evaluate if radical prostatectomy may positively influence cancer-specific survival (CSS), hormone-resistance-free time, metastasis-free time, and quality of life(QoL) of patients with prostate adenocarcinoma and seminal vesicle invasion, and also to update our thoughts about seminal vesicle biopsy.
  • Forty-six cases were diagnosed of seminal vesicle invasion after radical prostatectomy; 68 cases were diagnosed of seminal vesicle invasion after biopsy, not undergoing then surgery.
  • Cancer specific survival, time to hormone resistance from the start of hormonal treatment, metastasis free time and QoL, measured as need for hospital care, were compared between groups.
  • Median follow-up time was 52.6 mos.
  • RESULTS: There were not statistically significant differences between groups in CSS, time to hormone resistance, metastasis free time and QoL.
  • Primary grade and Gleason Score were independent predictors for CSS in the Cox regression test; clinical stage was independent predictor for time to hormone resistance.
  • CONCLUSIONS: Radical prostatectomy as monotherapy does not show a statistically significant influence on followup time, CSS, time to hormone resistance, metastasis free time or QoL in patients with prostate cancer and seminal vesicle invasion associated with other bad prognostic factors (unfavourable Gleason and PSA).
  • The value of seminal vesicle biopsy remains for the study of new multimodal treatments, such as chemotherapy + surgery, and it is to be defined in the planning of radio and cryosurgery.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Seminal Vesicles / pathology
  • [MeSH-minor] Aged. Biopsy. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283711.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Anscher MS, Clough R, Robertson CN, Prosnitz LR, Dahm P, Walther P, Donatucci CF, Albala DM, Febbo P, George DJ, Sun L, Moul JW: Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer Prostatic Dis; 2006;9(3):254-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between 1970 and 1983, 159 patients underwent RP for newly diagnosed adenocarcinoma of the prostate and were found to have positive surgical margins, extracapsular extension and/or seminal vesicle invasion.
  • The RT group generally received 45-50 Gy to the whole pelvis, then a boost to the prostate bed (total dose of 55-65 Gy).
  • The median time to failure in the surgery group was 7.5 vs 14.7 years in the RT group (P=0.1).
  • In contrast to recurrences, nearly half of deaths from prostate cancer occurred more than 10 years after treatment.
  • Despite its long natural history, death from prostate cancer was the most common cause of mortality in this population with locally advanced tumors, reflecting the need for more effective therapy.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Pelvis / radiation effects. Prostatectomy / methods. Radiation Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Treatment Failure

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880828.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


6. Lattouf JB, Mc Cormack M, Yelle L, Hadjeres R, Saad F: Recurrence of a non-seminomatous germ cell tumor in the seminal vesicle 20 years after initial diagnosis and treatment. Can J Urol; 2004 Aug;11(4):2350-1
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of a non-seminomatous germ cell tumor in the seminal vesicle 20 years after initial diagnosis and treatment.
  • We present a case of a pathologic stage 1, right sided, non-seminomatous germ cell tumor recurrence in the left seminal vesicle, 20 years after initial diagnosis and treatment.
  • At 24 months of follow-up after completion of chemotherapy, digital rectal and TRUS examinations revealed complete resolution of the lesion.
  • We believe that this tumor is a late metastasis to the contralateral seminal vesicle.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Middle Aged. Seminal Vesicles. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15380057.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Singh RP, Raina K, Deep G, Chan D, Agarwal R: Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res; 2009 Jan 15;15(2):613-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Silibinin treatment reduced the lower urogenital weight (including tumor, prostate, and seminal vesicle) by 40% (P < 0.05) without any toxicity in mice.
  • Silibinin decreased proliferating cell nuclear antigen expression and proliferating cells (P < 0.001) but increased cleaved caspase-3-positive cells (P < 0.01) and apoptotic cells (P < 0.001) and suppressed tumor microvessel density (P < 0.001) and vascular endothelial growth factor expression (P = 0.02).
  • CONCLUSIONS: These findings provide evidence for antitumor efficacy of silibinin against orthotopically growing prostate tumor in mice with multitargeted mechanistic insights and support its clinical investigation in prostate cancer.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5617-20 [11059749.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1051-9 [11007941.001]
  • [Cites] BioDrugs. 2001;15(7):465-89 [11520257.001]
  • [Cites] Oncogene. 2002 Mar 7;21(11):1759-67 [11896607.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3063-9 [12036915.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):225-43 [12085964.001]
  • [Cites] Cell Cycle. 2002 May-Jun;1(3):156-61 [12429925.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3512-9 [12429642.001]
  • [Cites] Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S18-27 [12570331.001]
  • [Cites] Curr Cancer Drug Targets. 2003 Jun;3(3):205-17 [12769689.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):933-9 [14504208.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):768-80 [14570043.001]
  • [Cites] Oncogene. 2003 Nov 13;22(51):8271-82 [14614451.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):1-11 [14965263.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6349-56 [15342425.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):1-9 [9422516.001]
  • [Cites] Eur Urol. 1999;35(5-6):342-50 [10325487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7490-5 [10377442.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5439-47 [15331580.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1188-202 [15558015.001]
  • [Cites] Urology. 2005 Sep;66(3):671-5 [16140113.001]
  • [Cites] Front Biosci. 2006;11:1164-88 [16146805.001]
  • [Cites] Mol Biotechnol. 2005 Oct;31(2):151-74 [16170216.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Jun;2(6):315-24 [16264989.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7465-74 [16288293.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):1053-69 [16205633.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):436-42 [16637061.001]
  • [Cites] Clin Transl Oncol. 2006 May;8(5):318-29 [16760006.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):751-78 [16954429.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1779-87 [16931911.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2435-43 [17041086.001]
  • [Cites] Invest New Drugs. 2007 Apr;25(2):139-46 [17077998.001]
  • [Cites] Cell Prolif. 2007 Jun;40(3):316-26 [17531077.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4469-77 [17297466.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1463-70 [17341659.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):11083-91 [18006855.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2567-74 [17916909.001]
  • [Cites] Clin Invest Med. 2008;31(1):E8-E15 [18312749.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1225-8 [10728680.001]
  • [Cites] FEBS Lett. 2001 Jan 19;488(3):179-84 [11163768.001]
  • (PMID = 19147767.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102514-05; United States / NCI NIH HHS / CA / R01 CA102514; United States / NCI NIH HHS / CA / CA102514; United States / NCI NIH HHS / CA / R01 CA102514-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antioxidants; 0 / Silymarin; 0 / Vascular Endothelial Growth Factor A; 4RKY41TBTF / silybin; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS81817; NLM/ PMC2629529
  •  go-up   go-down


8. Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y, Prostate Cancer Study Group: Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results. Int J Urol; 2004 May;11(5):295-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
  • BACKGROUND: The effects of preoperative androgen deprivation on the outcomes of prostate cancer patients who received radical prostatectomy and subsequent adjuvant endocrine therapy have not yet been fully evaluated.
  • METHODS: Patients with stage A(2), B or C prostate cancers were randomized to one of two groups: group I (n = 90), who received androgen deprivation (leuprolide and chlormadinone acetate) for 3 months followed by radical prostatectomy and subsequent adjuvant endocrine therapy (leuprolide alone), and group II (n = 86), who underwent the surgery followed by 3-month androgen deprivation (leuprolide and chlormadinone acetate) and subsequent adjuvant endocrine therapy (leuprolide alone).
  • The effects of preoperative androgen deprivation on survival, clinical relapse (serum prostate specific antigen, PSA, above the normal level, local recurrence, or distant metastases), and PSA relapse (PSA above the detectable level) were evaluated at 5 years or later after treatment.
  • In a subanalysis, no prostate cancer deaths or clinical relapses were noted in 29 patients with organ-confined disease (OCD: negativity of capsular invasion, seminal vesicle invasion, surgical margins or nodal involvement).
  • CONCLUSION: Preoperative androgen deprivation has no demonstrable benefit in 5-year outcomes for patients undergoing radical prostatectomy and adjuvant endocrine therapy.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Chlormadinone Acetate / therapeutic use. Leuprolide / therapeutic use. Prostatectomy. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Therapy, Combination. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Preoperative Care. Prostate-Specific Antigen / blood. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15147545.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0SY050L61N / Chlormadinone Acetate; EC 3.4.21.77 / Prostate-Specific Antigen; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


9. Miao M, Kong CZ, Li ZH, Liu XK, Sun ZX: [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma]. Zhonghua Wai Ke Za Zhi; 2009 May 15;47(10):728-30
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma].
  • OBJECTIVE: To investigate the clinical methods for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma.
  • Technique B was dissection along the vas deferens to the bladder wall circumferentially around the ipsilateral ureteral orifice and division of the lateral vesical ligament to reach the seminal vesicle.
  • Prophylactic intravesical chemotherapy included 3 method.
  • Method 1 was intraoperative intravesical chemotherapy and then administrated once a week, 10 times in total.
  • Method 2 was intraoperative intravesical chemotherapy and then administrated once a week from the 4(th) week after operation, 10 times in total.
  • Method 3 was intravesical chemotherapy was given once a week from the 4(th) week after operation, 10 times in total.
  • The time of follow-up was 1 to 10 years with regular cystoscopy.
  • The postoperative recurrence rates of bladder cancer in patients using 3 kinds of intravesical chemotherapy regimen were 17.9% (11/67), 20.8% (10/48) and 33.3% (17/51), respectively.
  • There was significant difference between the recurrence rates of patients using method 1 and method 3 intravesical chemotherapy (P < 0.05).
  • CONCLUSION: Complete removal of the bladder mucosa circumferentially around the ureteral orifice, administration of the intraoperative intravesical chemotherapy instillation and instillation once a week may be a useful approach to reduce the recurrence of bladder cancer after operation for renal pelvic carcinoma.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Postoperative Care. Retrospective Studies

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615202.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Ahmed SU, Meklat F, Shahriar M, Zhang J, Mastulov S, Giannakouros T, Jewell A, Zhang Y, Lim SH: SEMG-1 expression in early stage chronic lymphocytic leukemia. Cytotherapy; 2009;11(2):238-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These patients are, therefore, a suitable group for testing immunotherapeutic approaches to avoid problems of immunosuppression as a result of disease progression and chemotherapy.
  • In this study, we investigated the expression of SEMG-1 in early CLL to determine the suitability of SEMG-1 as a target for further development of tumor vaccines for early CLL.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Seminal Vesicle Secretory Proteins / metabolism
  • [MeSH-minor] Antibody Formation. Cancer Vaccines. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Neoplastic. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Immunohistochemistry. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction. ZAP-70 Protein-Tyrosine Kinase / genetics. ZAP-70 Protein-Tyrosine Kinase / immunology. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241194.001).
  • [ISSN] 1477-2566
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 088434; United States / NCI NIH HHS / CA / R01 CA 106283
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cancer Vaccines; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Seminal Vesicle Secretory Proteins; 0 / seminal vesicle-specific antigen; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


11. Tollefson MK, Slezak JM, Leibovich BC, Zincke H, Blute ML: Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc; 2007 Apr;82(4):422-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
  • OBJECTIVE: To assess the risk of local recurrence, systemic progression, and death from cancer among patients who experience biochemical relapse after radical retropubic prostatectomy and to stratify those patients by prostate-specific antigen (PSA) doubling time (DT).
  • The PSA-DT was calculated by log linear regression using all PSA values within 2 years of biochemical recurrence.
  • Of the 1064 patients with a calculable PSA-DT, 322 (30%) had a PSA-DT of less than 1 year, 357 (34%) had a PSA-DT of 1 to 9.9 years, and 385 (36%) had a PSA-DT of 10 years or more.
  • Patients with a PSA-DT of 10 years or more were less likely to have a higher preoperative PSA level, Gleason score, advanced pathologic stage, and seminal vesicle invasion.
  • Patients with a PSA-DT of 10 years or more were at low risk of local recurrence (hazard ratio [HR], 0.09; 95% confidence interval [CI], 0.06-0.14; compared with patients with a PSA-DT of <1 year), systemic progression (HR, 0.05; 95% CI, 0.02-0.13), or death from cancer (HR, 0.15; 95% CI, 0.05-0.43).
  • CONCLUSIONS: Prostate-specific antigen DT is an independent predictor of clinical disease recurrence and mortality after surgical biochemical failure.
  • Risk stratification into high-, intermediate-, and low-risk categories based on the PSA-DT provides helpful clinical information and assists in the development of salvage therapy trials.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Disease Progression. Disease-Free Survival. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Time Factors

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418069.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


12. Kasibhatla M, Peterson B, Anscher MS: What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate? Prostate Cancer Prostatic Dis; 2005;8(2):167-73
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate?
  • The purpose of this paper to identify the optimal therapy after radical prostatectomy (RP) for patients with adenocarcinoma of the prostate invading the seminal vesicles (pT3bN0M0 or SVI).
  • A PubMed search using the keywords 'prostate', 'seminal vesicle', 'prostatectomy', 'radiotherapy', 'androgen blockade' was performed to identify literature regarding rates of disease failure in patients with SVI who are observed or treated with androgen blockade (AB), radiotherapy (RT) or RT + AB after RP.
  • Seminal vesicle invasion confers a poor prognosis after RP.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Androgen Antagonists / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Seminal Vesicles / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711603.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists
  • [Number-of-references] 33
  •  go-up   go-down


13. Zincke H, Lau W, Bergstralh E, Blute ML: Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol; 2001 Dec;166(6):2208-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
  • PURPOSE: Recent prospective randomized studies have shown that adjuvant hormonal therapy combined with local treatment can significantly improve overall survival in patients with locally advanced disease.
  • This finding challenges the previous belief that adjuvant hormonal therapy may not be beneficial for minimal stages TxN + M0 or less prostate cancer, particularly when combined with local treatment.
  • We reviewed the benefits of adjuvant hormonal therapy in patients at risk for disease progression, especially when administered after radical prostatectomy.
  • MATERIALS AND METHODS: We retrospectively reviewed the current literature and evaluated clinical information on stage pT3b cancer from a large single institution prostate cancer database to determine the current role of adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
  • RESULTS: Retrospective experimental and clinical studies have proved the impact of adjuvant hormonal therapy for decreasing prostate specific antigen (PSA) and clinical disease progression in patients with regionally limited prostatic cancer.
  • Our literature review and current data from the Mayo Clinic database show that adjuvant hormonal therapy after prostatectomy has a significant impact on prostate specific antigen (PSA) progression but it also decreases systemic progression and cause specific death in patients with stage pT3b and lymph node positive disease.
  • A recent prospective randomized trial showed a significant decrease in cancer death in N+ cases when adjuvant hormonal therapy was administered after radical prostatectomy, supporting previous Mayo Clinic data on N+ disease that favors combination therapy.
  • In the PSA era, that is 1987 and after, our database data on stage pTxN+ cancer indicates that radical prostatectomy and hormonal therapy for single node positive disease resulted in 94% 10-year cause specific survival, which was not significantly different from the rate in patients with N0 disease after adjusting for local stage, Gleason grade, margins, ploidy, PSA and adjuvant hormonal therapy.
  • CONCLUSIONS: Our literature review, including prospective randomized studies, and more recent results in the PSA era from our database indicate that early adjuvant hormonal therapy has a significant impact on time to progression and cause specific survival in patients with seminal vesicle invasion and limited lymph node disease who undergo radical prostatectomy, although in a retrospective nonrandomized study.
  • Future prospective studies with longer followup are needed to evaluate the potential benefit of adjuvant treatment in regard to survival for stages pT2 and pT3a disease with unfavorable pathological variables.
  • [MeSH-major] Prostatectomy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Male. Neoplasm Staging. Retrospective Studies. Survival Rate


14. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N: Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J Pathol; 2005 Aug;206(4):423-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has recently been demonstrated that phosphorylation of FADD at serine 194 plays an important role in the induction of apoptosis by anti-cancer drugs in human prostate cancer cells.
  • The positivity for phosphorylated FADD was significantly lower for patients with a Gleason score greater than or equal to 7, a positive surgical margin, extracapsular or seminal vesicle invasion.
  • In addition, a relationship was also apparent in cancer cells refractory to neoadjuvant hormonal therapy.
  • Interestingly, in Gleason score 3 + 4 tumours, the positivity for FADD phosphorylation was statistically increased by neoadjuvant hormonal therapy, resulting in a reduced percentage of cases with a positive surgical margin and extracapsular invasion.
  • These results clearly demonstrate that transition from phosphorylated FADD to the non-phosphorylated form might be associated with carcinogenesis and that induction of FADD phosphorylation could therefore be a target for chemohormonal therapy of human prostate cancer.
  • [MeSH-minor] Aged. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Apoptosis / physiology. Biomarkers, Tumor / analysis. Cell Division. Cell Line, Tumor. Cell Survival / physiology. Cells, Cultured. Disease Progression. Drug Therapy, Combination. Epithelial Cells / metabolism. Gonadotropin-Releasing Hormone / agonists. Humans. Immunohistochemistry / methods. Male. Middle Aged. Neoplasm Proteins / metabolism. Nitriles. Phosphorylation. Prostate-Specific Antigen / analysis. Tosyl Compounds

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Pathological Society of Great Britain and Ireland
  • (PMID = 15906275.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Arabidopsis Proteins; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Nitriles; 0 / Tosyl Compounds; 33515-09-2 / Gonadotropin-Releasing Hormone; A0Z3NAU9DP / bicalutamide; EC 1.14.19.- / Fatty Acid Desaturases; EC 1.14.99.- / Fad7 protein, Arabidopsis; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


15. Suckow MA, Rosen ED, Wolter WR, Sailes V, Jeffrey R, Tenniswood M: Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine. Cancer Immunol Immunother; 2007 Aug;56(8):1275-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
  • To examine if a xenogeneic tissue vaccine could stimulate protective immunity in a human prostate cancer cell line, a vaccine was produced by glutaraldehyde fixation of harvested PAIII prostate cancer cells tumors (GFT cell vaccine) from Lobund-Wistar rats.
  • Immunocompetent Ncr-Foxn1<nu> mice were vaccinated with the GFT cell vaccine four times, 7 days apart.
  • Results showed that vaccination with GFT cells resulted in increased serum antibody to a PAIII cell lysate; reduced weight of the prostate/seminal vesicle complex and reduced incidence of prostate cancer in nude mice; increased splenocyte supernatant levels of TNF-alpha, IL-2, IFN-gamma and IL-12, cytokines associated with Th1 immunity; and increased splenocyte supernatant levels of IL-4 and IL-10, cytokines associated with Th2 immunity.
  • In summary, the results suggest that use of a xenogeneic tissue vaccine can stimulate protective immunity against human prostate cancer cells.
  • [MeSH-major] Adenocarcinoma / therapy. Cancer Vaccines / therapeutic use. Immunotherapy, Active. Prostatic Neoplasms / therapy
  • [MeSH-minor] Animals. Antibodies, Neoplasm / blood. Cell Line, Tumor / immunology. Cells, Cultured / immunology. Cells, Cultured / secretion. Coculture Techniques. Cytokines / secretion. Disease Progression. Drug Screening Assays, Antitumor. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Organ Size. Spleen / immunology. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / secretion. Tumor Burden. Vaccination. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242926.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 0 / Cytokines
  •  go-up   go-down


16. Singh RP, Raina K, Sharma G, Agarwal R: Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res; 2008 Dec 1;14(23):7773-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
  • Herein, for the first time, we investigated the effect and associated mechanisms of silibinin phosphatidylcholine (silybin-phytosome) on established prostate tumors in transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
  • EXPERIMENTAL DESIGN: Twenty-week-old TRAMP male mice having palpable prostate tumor were fed with control or 0.5% and 1%, w/w, silybin-phytosome diets for 11 weeks and then sacrificed.
  • RESULTS: Dietary silibinin inhibited the growth of prostate tumors (up to 60%, P < 0.001) and suppressed tumor progression from prostatic intraepithelial neoplasia to differentiated adenocarcinoma and poorly differentiated adenocarcinoma, with a complete absence of poorly differentiated adenocarcinoma at higher doses.
  • It also inhibited the incidence of tumor invasion of seminal vesicle (up to 81%, P < 0.001) with complete absence of distant metastasis.
  • Silibinin moderately inhibited tumor cell proliferation and induced apoptosis, but strongly suppressed tumor microvessel density (up to 60%, P < 0.001), vascular endothelial growth factor, and vascular endothelial growth factor receptor-2 expression.
  • CONCLUSIONS: Overall, silibinin treatment of TRAMP mice bearing prostate tumor inhibited tumor growth, progression, local invasion, and distant metastasis involving suppression of tumor angiogenesis and epithelial-mesenchymal transition.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Nov 15;67(22):11083-91 [18006855.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):403-10 [17574861.001]
  • [Cites] Cancer Invest. 2008 Feb;26(1):104-8 [18181052.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2043-50 [18339887.001]
  • [Cites] Biochim Biophys Acta. 2008 Apr;1785(2):156-81 [18166163.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2567-74 [17916909.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5617-20 [11059749.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2736-43 [11289156.001]
  • [Cites] BioDrugs. 2001;15(7):465-89 [11520257.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3063-9 [12036915.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Prostate. 2002 Sep 1;52(4):253-63 [12210485.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):525-32 [12479270.001]
  • [Cites] Urol Res. 2003 Feb;30(6):347-55 [12599013.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] J Cell Biol. 1991 Apr;113(1):173-85 [2007622.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Toxicol Pathol. 1996 Jul-Aug;24(4):502-4 [8864193.001]
  • [Cites] J Cell Biochem Suppl. 1996;25:156-64 [9027613.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1920-9 [9581834.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7490-5 [10377442.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1188-202 [15558015.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):436-46 [15928674.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):1053-69 [16205633.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 May;7(5):359-71 [16633338.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):436-42 [16637061.001]
  • [Cites] Endothelium. 2006 Mar-Apr;13(2):63-9 [16728325.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):846-55 [16788158.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):751-78 [16954429.001]
  • [Cites] Invest New Drugs. 2007 Apr;25(2):139-46 [17077998.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5789-97 [17575146.001]
  • [Cites] Urol Oncol. 2007 Sep-Oct;25(5):413-9 [17826663.001]
  • [CommentIn] Clin Cancer Res. 2008 Dec 1;14(23):7581-2 [19047081.001]
  • (PMID = 19047104.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102514-05; United States / NCI NIH HHS / CA / R01 CA102514; United States / NCI NIH HHS / CA / R01 CA102514-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / Silymarin; 0 / Vimentin; 0 / silybin-phytosome; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ NIHMS82719; NLM/ PMC2639624
  •  go-up   go-down


17. Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML: E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol; 2001 Jul;32(7):690-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
  • To address these variations, we undertook a study to systematically evaluate E-cadherin expression in a broad range of prostate tissue.
  • Benign prostate, clinically localized prostate cancer, and hormone-refractory metastatic prostate cancer were analyzed under uniform conditions using high-density tissue microarrays (TMA).
  • Benign and atrophic prostate tissue and high-grade prostatic intraepithelial neoplasia (PIN) were also included from the clinically localized cases.
  • There was a statistically significant association between aberrant E-cadherin expression and larger tumor size (P =.01).
  • No significant associations were seen with extraprostatic extension and seminal vesicle invasion.
  • A statically significant association between aberrant E-cadherin expression and larger tumor size was identified.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Drug Resistance, Neoplasm. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology






Advertisement